TRVI Stock Forecast & Price Target

Trevi Therapeutics is well positioned because Haduvio targets a large, underserved chronic cough market across IPF, non-IPF ILD, and RCC, with management estimating a US TAM of more than $30B and peak-sales potential above $6B. Its differentiated central-and-peripheral mechanism, strong Phase 2 efficacy in RIVER, and broad clinical profile support the view that it can become both first-in-class and best-in-class while facing limited competition and a formidable IP moat. The removal of the most advanced RCC competitor, along with cash runway into 2030, gives Trevi a clearer standalone path to fund its IPF Phase 3 program, generate RCC Phase 2b data, and retain strategic optionality.

Trevi Therapeutics is viewed negatively because the broader chronic cough landscape has already shown how difficult it is to translate early signals into durable late-stage efficacy, especially in heterogeneous populations. The cited camlipixant experience suggests that even therapies with earlier supportive data can fail in Phase 3 when benefits do not reproduce consistently across pivotal studies, raising concern that Haduvio may face similar translational and regulatory hurdles. More broadly, the reliance on a single oral nalbuphine ER program in a clinical-stage model leaves the company highly exposed to development setbacks, with limited diversification to offset a negative trial outcome.